Gencellmed

Gencellmed was founded in 2019, the first startup of the New Drug Division at KIRAMS.
(Korea Institute of Radiological & Medical Sciences)

• GenCellMed is a portmanteau of Gene + Cell + Medicine.
• Our goal is to develop Best-in-Class next-generation viral therapies to treat human diseases with unmet clinical needs.
  The core backbone of virus-based therapies uses HSV-1 (Herpes Simplex Virus-1).
  The therapeutic virus specifically binds to the disease cells by the patented First-in-Class Self-targeting and Double-targeting technologies.

GCM designs therapeutic viruses for
the infection of only cancer cells and selective replication in cancer cells.

• Only target disease cells by binding to predefined biomarkers, thus not harming neighboring normal cells.
• Only produce viral progeny in disease cells, thus protecting other body organs.
• Only stimulate the immune response in the target region, thus optimizing immunotherapy goals.

• SMART™ Platform: The four genetic engineering technologies are embedded in ONE VIRAL PARTICLE

  GCM Therapeutic Virus Engineering Technology

  SMART Platform

  (Synthetic & Multi-Antigen Retargeting Technology)

  Efficiently infecting disease cells, Production of therapeutic virus ONLY in disease cells,
  & Use patient’s immune system to synergize to destroy disease cells

• 1Self-Targeting by Adapter to bind the key biomarker on the target cell surface

  2Protein engineering of viral envelope protein for binding efficiency to target cel

  3Double targeting by combination of self-targeting adapter(①) and modified gH(②)

  4Selective-Replication of the virus only in target disease cells

  5Strong Immunotherapy effects by delivering chemokine and cytokine genes to the disease region

• SMART™ Expandability

Available in various indication

A single virus can multi-target tumor tissue

World’s first Triple-targeting on tumors with one virus

• HSV Oncolytic Virus to kill ONLY cancer cells
• How? IT/IP/IV Cancer targeting + Selective replication by hTERT
• Core Tech: SMART™ Platform (Synthetic & Multi-Antigen Retargeting Technology)
• Disease: Ovarian cancer (high EpCAM)
• Current stage: Preclinical